PMLS Virtual Series 2021 – Precision Health

On Demand Now Click Here

April 13, 2021

8:57am      EST 

Welcome and Opening Remarks

Nigel Russell, Founder and President, Precision Medicine Leaders’ Summits, The Journal of Precision Medicine

9:00-9:45am EST

Keynote – Integrating Precision Medicine and Population Health: Challenges and Opportunities

Sandro Galea, MD, MPH, DrPH, Dean, Robert A. Knox Professor, School of Public Health, Boston University

Precision medicine approaches hold enormous promise to focus diagnostic approaches and potentially to improve treatment opportunities over a range of diseases.  However, the promise of these approaches has largely lagged their achievement.  The role that context plays in shaping our response to treatment is, in no small part, responsible for this promise-achievement gap. Population health science offers an approach to understand how we can integrate influence at various levels—from individual to environmental—in prevention and treatment. A forward looking agenda then integrates the building blocks of precision medicine and population health.

9:50-10:45am  EST

The Value of Making the Correct Diagnosis

Moderator: Andrew L. Pecora, MD, FACP, CPE, Executive Chairman and Chief Executive Officer, Outcomes Matter Innovations, LLC

Panelists: Maher Albitar, MD, Founder, Chief Executive Officer, Chief Medical Officer, Genomic Testing Cooperative, LCA; David Gambino, MS, Vice President, Transformation & Pharmacy, Horizon Blue Cross Blue Shield of New Jersey 

  • Clinician’s perspective  – Andrew Pecora, MD, FACP, CPE – Executive Chairman, CEO – OMI
  • Laboratory perspective – Maher Albitar, MD – CEO/CMO, Genomic Testing Cooperative
  • Payor perspective – David Gambino, Vice President Transformation and Chief Pharmacy Officer · ‎Horizon Blue Cross Blue Shield of New Jersey

10:50-11:45am  EST

What is needed to truly deliver precision health care?

Brad Bostic, Chairman and Chief Executive Officer, hc1; Brian Patty, MD, Chief Medical Informatics Officer, Medix Technology

Despite expectations for individualized care, a majority of the U.S. healthcare system operates under a one-size-fits-all, trial-and-error care delivery model. This outdated practice results in missed diagnoses, adverse drug reactions, protracted illnesses, and premature death, wasting anywhere from $760 billion to $935 billion every year. We know precision health care will improve outcomes, save lives and reduce waste and costs, but why are healthcare systems and providers slow to adopt? This panel of experts from across the care continuum will discuss the reasons why and solutions for delivering precision health to all patients.

11:50-12:55pm  EST 

Disrupting Precision Health with Next-generation Proteomics 

Moderator: Kevin Hrusovsky, MBA, President, Chairman, Chief Executive Officer, Quanterix

Panelist: Kevin Knopp, PhD, Co-founder and Chief Executive Officer, 908 Devices Inc;  Tatiana Plavina, PhD, Head, Bioanalytical Sciences and Neuro Biomarkers; Clinical Biomarker Innovation and Development, Takeda; Charlotte Teunissen, PhD, Professor, Neurochemistry, UMS Amsterdam

By bringing essential testing into the home, the COVID-19 pandemic has ushered in a new age in diagnostics and preventative care. While genetic testing is generally the most widely recognized, fulfilling the true promise for precision health lies in the power of the protein biomarker to see and detect disease at its earliest stages. In this panel discussion, healthcare visionary, Powering Precision Health Founder and CEO of Quanterix, Kevin Hrusovsky, and panelists will explore the potential to harness ultra-sensitive protein quantitation to deliver non-invasive blood testing solutions for homecare use, such as those reliant on a capillary (finger prick) sample or dried blood swab rather than a traditional blood draw. Beginning with COVID-19, and expanding into other critical disease categories, including oncology and neurology, these regular blood-based biomarker screenings have the potential to aid in disease prevention, study critical research questions (i.e., immunity and treatment response), and lower healthcare costs through early intervention. Hrusovsky and his panelists will also share early efforts to realize this vision through COVID-19 serosurveillance efforts with some of the world’s largest payor groups and discuss how this is laying the groundwork for a disruption in medicine that will re-shape the diagnostics industry.

1:00-1:45pm      EST

Personalized Approaches to Hypertension: Opportunities and Obstacles

Donna K. Arnett, PhD, MSPH, Dean, College of Public Health; Professor, Epidemiology, University of Kentucky

Elevated blood pressure is a common condition experienced by over a billion people worldwide. It is a serious risk factor for multiple cardiovascular and renal disorders. About 30–50% of risk variation for hypertension comes from genetic factors. Monogenic forms of hypertension are relatively rare and are caused by variants in a single gene. Diagnosis of the type of monogenic hypertension has been successfully used to guide therapy. Essential hypertension is relatively common and generally understood to be caused by multiple interacting environmental, genomic, and epigenomic factors. More than 1500 significant genomic associations with blood pressure-related traits have been reported, including some pharmacogenomic associations. This presentation will discuss current efforts to leverage such findings to improve essential hypertension pharmacotherapy. Challenges faced by those working in essential hypertension pharmacogenomics will also be considered, such as certain intrinsic properties of the phenotype, the lack of functional follow up studies, incomplete understanding of blood pressure pathways, and heterogeneity of findings across racial groups

1:45pm      EST 

Closing Remarks

Nigel Russell, Founder and President, Precision Medicine Leaders’ Summits, The Journal of Precision Medicine